Marcin A Zarowski

Prof. Marcin A Zarowski

Department of Developmental Neurology, Poznan University of Medical Sciences, Przybyszewski 49 Str., 60-355 Poznań, Poland
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KWKamil Wdowiak
Kamil Wdowiak
NRNatalia Rosiak
Natalia Rosiak
ETEwa Tykarska
Ewa Tykarska
MZMarcin A Zarowski
Marcin A Zarowski
APAnita Płazińska
Anita Płazińska
Judyta Cielecka-PiontekJudyta Cielecka-Piontek
Judyta Cielecka-Piontek
This study aimed at obtaining hesperidin (Hed) and hesperetin (Het) systems with HP-β-CD by means of the solvent evaporation method. The produced systems were identified using infrared spectroscopy (FT-IR), X-ray powder diffraction (XRPD), and differential scanning calorimetry (DSC). Moreover, in silico docking and molecular dynamics studies were performed to assess the most preferable site of interactions between tested compounds and HP-β-CD. The changes of physicochemical properties (solubility, dissolution rate, and permeability) were determined chromatographically. The impact of modification on biological activity was tested in an antioxidant study as well as with regards to inhibition of enzymes important in pathogenesis of neurodegenerative diseases. The results indicated improvement in solubility over 1000 and 2000 times for Hed and Het, respectively. Permeability studies revealed that Hed has difficulties in crossing biological membranes, in contrast with Het, which can be considered to be well absorbed. The improved physicochemical properties influenced the biological activity in a positive manner by the increase in inhibitory activity on the DPPH radical and cholinoesterases. To conclude the use of HP-β-CD as a carrier in the formation of an amorphous inclusion complex seems to be a promising approach to improve the biological activity and bioavailability of Hed and Het.

10 December 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ESElżbieta Studzińska-Sroka
Elżbieta Studzińska-Sroka
Aleksandra Majchrzak-CelińskaAleksandra Majchrzak-Celińska
Aleksandra Majchrzak-Celińska
Przemysław ZalewskiPrzemysław Zalewski
Przemysław Zalewski
Dominik SzwajgierDominik Szwajgier
Dominik Szwajgier
EBEwa Baranowska-Wójcik
Ewa Baranowska-Wójcik
Judyta Cielecka-PiontekJudyta Cielecka-Piontek
Judyta Cielecka-Piontek
Lichens are a source of chemical compounds with valuable biological properties, structurally predisposed to penetration into the central nervous system (CNS). Hence, our research aimed to examine the biological potential of lipophilic extracts of Parmelia sulcata, Evernia prunastri, Cladonia uncialis, and their major secondary metabolites, in the context of searching for new therapies for CNS diseases, mainly glioblastoma multiforme (GBM). The extracts selected for the study were standardized for their content of salazinic acid, evernic acid, and (−)-usnic acid, respectively. The extracts and lichen metabolites were evaluated in terms of their anti-tumor activity, i.e., cytotoxicity against A-172 and T98G cell lines and anti-IDO1, IDO2, TDO activity, their anti-inflammatory properties exerted by anti-COX-2 and anti-hyaluronidase activity, antioxidant activity, and anti-acetylcholinesterase and anti-butyrylcholinesterase activity. The results of this study indicate that lichen-derived compounds and extracts exert significant cytotoxicity against GBM cells, inhibit the kynurenine pathway enzymes, and have anti-inflammatory properties and weak antioxidant and anti-cholinesterase properties. Moreover, evernic acid and (−)-usnic acid were shown to be able to cross the blood-brain barrier. These results demonstrate that lichen-derived extracts and compounds, especially (−)-usnic acid, can be regarded as prototypes of pharmacologically active compounds within the CNS, especially suitable for the treatment of GBM.

5 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ESElżbieta Studzińska-Sroka
Elżbieta Studzińska-Sroka
Aleksandra Majchrzak-CelińskaAleksandra Majchrzak-Celińska
Aleksandra Majchrzak-Celińska
Przemysław ZalewskiPrzemysław Zalewski
Przemysław Zalewski
Dominik SzwajgierDominik Szwajgier
Dominik Szwajgier
EBEwa Baranowska-Wójcik
Ewa Baranowska-Wójcik
Judyta Cielecka-PiontekJudyta Cielecka-Piontek
Judyta Cielecka-Piontek
Lichen secondary metabolites are characterized by huge pharmacological potential. Our research focused on assessing the anticancer and neuroprotective activity of Hypogymnia physodes acetone extract (HP extract) and physodic acid, its major component. The antitumor properties were evaluated by cytotoxicity analysis using A-172, T98G, and U-138 MG glioblastoma cell lines and by hyaluronidase and cyclooxygenase-2 (COX-2) inhibition. The neuroprotective potential was examined using COX-2, tyrosinase, acetylcholinesterase (AChE), and butyrylcholinesterase (BChE) activity tests. Moreover, the antioxidant potential of the tested substances was examined, and the chemical composition of the extract was analyzed. For physodic acid, the permeability through the blood–brain barrier using Parallel Artificial Membrane Permeability Assay for the Blood–Brain Barrier assay (PAMPA-BBB) was assessed. Our study shows that the tested substances strongly inhibited glioblastoma cell proliferation and hyaluronidase activity. Besides, HP extract diminished COX-2 and tyrosinase activity. However, the AChE and BChE inhibitory activity of HP extract and physodic acid were mild. The examined substances exhibited strong antioxidant activity. Importantly, we proved that physodic acid crosses the blood–brain barrier. We conclude that physodic acid and H. physodes should be regarded as promising agents with anticancer, chemopreventive, and neuroprotective activities, especially regarding the central nervous system diseases.

Verified
Journal Article
Open access
PDF file
Anna Stasiłowicz-KrzemieńAnna Stasiłowicz-Krzemień
Anna Stasiłowicz-Krzemień
MGMichał Gołębiewski
Michał Gołębiewski
APAnita Płazińska
Anita Płazińska
WPWojciech Plazinski
Wojciech Plazinski
Andrzej MiklaszewskiAndrzej Miklaszewski
Andrzej Miklaszewski
Judyta Cielecka-PiontekJudyta Cielecka-Piontek
Judyta Cielecka-Piontek
Background: Naringenin (NAR) is a flavonoid with excellent antioxidant and neuroprotective potential that is limited by its low solubility. Thus, solid dispersions with β-cyclodextrin (β-CD), hydroxypropyl-β-cyclodextrin (HP-β-CD), hydroxypropylmethylcellulose (HPMC), and microenvironmental pH modifiers were prepared. Methods: The systems formation analysis was performed by X-Ray Powder Diffraction (XRPD) and Fourier-transform infrared spectroscopy (FT-IR). Water solubility and dissolution rates were studied with a pH of 1.2 and 6.8. In vitro permeability through the gastrointestinal tract (GIT) and the blood-brain barrier (BBB) was assessed with the parallel artificial membrane permeability assay (PAMPA) assay. The antioxidant activity was studied with the 2,2′-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid (ABTS) and cupric ion reducing antioxidant capacity (CUPRAC) assays, while in vitro enzymes studies involved the inhibition of acetylcholinesterase, butyrylcholinesterase, and tyrosinase. For the most promising system, in silico studies were conducted. Results: NAR solubility was increased 458-fold by the solid dispersion NAR:HP-β-CD:NaHCO3 in a mass ratio of 1:3:1. The dissolution rate was elevated from 8.216% to 88.712% in a pH of 1.2 and from 11.644% to 88.843% in a pH of 6.8 (within 3 h). NAR GIT permeability, described as the apparent permeability coefficient, was increased from 2.789 × 10−6 cm s−1 to 2.909 × 10−5 cm s−1 in an acidic pH and from 1.197 × 10−6 cm s−1 to 2.145 × 10−5 cm s−1 in a basic pH. NAR BBB permeability was established as 4.275 × 10−6 cm s−1. The antioxidant activity and enzyme inhibition were also increased. Computational studies confirmed NAR:HP-β-CD inclusion complex formation. Conclusions: A significant improvement in NAR solubility was associated with an increase in its biological activity.

11 May 2012 in Epilepsia
Verified
Journal Article
Closed access
PDF file
SRSriram Ramgopal
Sriram Ramgopal
ASAneri Shah
Aneri Shah
MZMarcin A Zarowski
Marcin A Zarowski
MVMartina Vendrame
Martina Vendrame
MGMatthew Gregas
Matthew Gregas
KSKothare Sanjeev
Kothare Sanjeev

1 December 2014 in Pharmacological Reports
Verified
Journal Article
Closed access
BSBarbara Steinborn
Barbara Steinborn
MZMarcin A Zarowski
Marcin A Zarowski
AWAnna Winczewska-Wiktor
Anna Winczewska-Wiktor
MWMarlena Wójcicka
Marlena Wójcicka
JMJustyna Młodzikowska-Albrecht
Justyna Młodzikowska-Albrecht
JLJacek Losy
Jacek Losy